Physician profile
William R Pascal
NPI 1558474627
$1,677.86
in general payments reported to CMS, 2019-2025
20 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $147 · 2020: $296 · 2021: $45.34 · 2022: $155 · 2023: $174 · 2024: $415 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $857 · Education: $179.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $856.79 |
| Education | $178.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $257.85 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $245.34 | 2024-2025 | Opsumit, Uptravi |
| Vapotherm INC | $186.78 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.70 | 2023-2025 | Jascayd, Ofev |
| Mallinckrodt Hospital Products INC. | $119.74 | 2020 | |
| Ambu INC. | $96.30 | 2024-2025 | |
| Pfizer INC. | $93.79 | 2019-2025 | |
| Glaxosmithkline, LLC. | $80.52 | 2023-2025 | Trelegy Ellipta |
| Insmed, INC. | $73.41 | 2024-2025 | Arikayce |
| Chiesi USA, INC. | $60.59 | 2023-2025 | Cleviprex |
| Fisher & Paykel Healthcare INC | $41.11 | 2024 | Fisher & Paykel Healthcare |
| Inspire Medical Systems, INC. | $40.74 | 2025 | Inspire |
| Janssen Pharmaceuticals, INC | $39.51 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $33.03 | 2023 | Dupixent |
| Csl Behring | $30.58 | 2024 | Kcentra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $26.10 | 2023 | Tezspire |
| Abbvie INC. | $25.19 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $21.91 | 2023 | Tezspire |
| 3b Medical, INC. | $20.67 | 2023 | Luna |
| Merck Sharp & Dohme LLC | $19.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Pascal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.